Tirzepatide denied as not FDA-approved for this use by Cigna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Tirzepatide
## Why Cigna May Deny Tirzepatide as "Not FDA-Approved"
This denial is one of the most straightforward to challenge. It typically arises in one of two situations: (1) the denial is factually incorrect — tirzepatide has FDA approval for specific indications, and if your prescription matches an approved indication, the denial contradicts the public regulatory record; or (2) the prescription is for an indication not currently listed on the FDA-approved label, in which case a stronger evidentiary showing is required.
Before doing anything else, retrieve the current FDA-approved prescribing label from DailyMed (dailymed.nlm.nih.gov) and confirm whether the prescribed indication is listed. If it is, the appeal is straightforward. If it is not, the appeal path shifts to an off-label medical-necessity argument.
## Your Federal Appeal Rights
Under ACA §2719 and ERISA §503, you are entitled to a full internal appeal and independent external review regardless of the denial reason stated. File the internal appeal within 180 days of the denial notice. External review is available for approximately 4 months after final internal denial. Expedited review is available when clinical urgency applies.
## Concrete Appeal Steps
1. Pull the current FDA label from DailyMed and confirm the indication status. 2. Request Cigna's coverage/medical policy for tirzepatide and the specific policy basis for the "not FDA-approved" determination. 3. If the indication is FDA-approved: submit the label with the relevant section highlighted and request reversal. The denial is factually unsupported. 4. If the indication is off-label: have your prescriber compile peer-reviewed clinical evidence and cite the applicable professional society guideline (e.g., relevant ADA, AACE/ACE, or Obesity Medicine Association guidance). 5. File the internal appeal with supporting documentation. 6. If denied, request external review.
## Documentation to Gather
- Current FDA prescribing label (from DailyMed, with retrieval date noted)
- Diagnosis confirmation: chart notes and diagnostic codes establishing the indication
- Prescriber medical-necessity letter: for FDA-approved indications, a brief letter confirming the diagnosis matches the approved indication; for off-label, a full evidence summary
- Professional society guideline citation: prescriber cites the relevant guideline organization by name
## Criteria-Mapping Structure
The critical mapping for this denial type is: Cigna's stated basis for "not FDA-approved" → the FDA label's current approved indication list. If these do not align, the denial is factually wrong and the mapping itself is your primary appeal argument. Present it clearly, attach the label, and request reversal without extensive additional documentation.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →